S&P 500   3,157.73 (+0.51%)
DOW   28,056.24 (+0.52%)
QQQ   205.70 (+0.35%)
AAPL   269.64 (-0.42%)
FB   199.22 (-1.50%)
MSFT   151.99 (+0.19%)
GOOGL   1,343.09 (-0.09%)
AMZN   1,755.79 (+0.40%)
CGC   21.08 (+4.10%)
NVDA   221.33 (+1.84%)
MU   50.69 (+2.90%)
BABA   204.14 (-0.24%)
TSLA   359.50 (+1.93%)
T   38.35 (+0.45%)
ACB   2.58 (+5.31%)
NFLX   296.63 (-0.77%)
GILD   67.64 (-0.21%)
DIS   147.66 (+0.05%)
S&P 500   3,157.73 (+0.51%)
DOW   28,056.24 (+0.52%)
QQQ   205.70 (+0.35%)
AAPL   269.64 (-0.42%)
FB   199.22 (-1.50%)
MSFT   151.99 (+0.19%)
GOOGL   1,343.09 (-0.09%)
AMZN   1,755.79 (+0.40%)
CGC   21.08 (+4.10%)
NVDA   221.33 (+1.84%)
MU   50.69 (+2.90%)
BABA   204.14 (-0.24%)
TSLA   359.50 (+1.93%)
T   38.35 (+0.45%)
ACB   2.58 (+5.31%)
NFLX   296.63 (-0.77%)
GILD   67.64 (-0.21%)
DIS   147.66 (+0.05%)
S&P 500   3,157.73 (+0.51%)
DOW   28,056.24 (+0.52%)
QQQ   205.70 (+0.35%)
AAPL   269.64 (-0.42%)
FB   199.22 (-1.50%)
MSFT   151.99 (+0.19%)
GOOGL   1,343.09 (-0.09%)
AMZN   1,755.79 (+0.40%)
CGC   21.08 (+4.10%)
NVDA   221.33 (+1.84%)
MU   50.69 (+2.90%)
BABA   204.14 (-0.24%)
TSLA   359.50 (+1.93%)
T   38.35 (+0.45%)
ACB   2.58 (+5.31%)
NFLX   296.63 (-0.77%)
GILD   67.64 (-0.21%)
DIS   147.66 (+0.05%)
S&P 500   3,157.73 (+0.51%)
DOW   28,056.24 (+0.52%)
QQQ   205.70 (+0.35%)
AAPL   269.64 (-0.42%)
FB   199.22 (-1.50%)
MSFT   151.99 (+0.19%)
GOOGL   1,343.09 (-0.09%)
AMZN   1,755.79 (+0.40%)
CGC   21.08 (+4.10%)
NVDA   221.33 (+1.84%)
MU   50.69 (+2.90%)
BABA   204.14 (-0.24%)
TSLA   359.50 (+1.93%)
T   38.35 (+0.45%)
ACB   2.58 (+5.31%)
NFLX   296.63 (-0.77%)
GILD   67.64 (-0.21%)
DIS   147.66 (+0.05%)
Log in

OTCMKTS:PPCB - Propanc Biopharma Stock Price, Forecast & News

$0.20
-0.05 (-19.99 %)
(As of 12/12/2019 02:20 PM ET)
Today's Range
$0.20
Now: $0.20
$0.25
50-Day Range
$0.25
MA: $0.46
$0.95
52-Week Range
$0.06
Now: $0.20
$28.50
Volume66,218 shs
Average Volume27,333 shs
Market Capitalization$262,131.00
P/E RatioN/A
Dividend YieldN/A
Beta4.28
Propanc Biopharma, Inc., a development-stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. The company's lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. Propanc Biopharma, Inc. has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was founded in 2007 and is based in Camberwell, Australia.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PPCB
CUSIPN/A
Phone610398820780

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($4.61) per share

Profitability

Net Income$-5,760,000.00

Miscellaneous

Employees1
Market Cap$262,131.00
Next Earnings Date2/13/2020 (Estimated)
OptionableNot Optionable

Receive PPCB News and Ratings via Email

Sign-up to receive the latest news and ratings for PPCB and its competitors with MarketBeat's FREE daily newsletter.


Propanc Biopharma (OTCMKTS:PPCB) Frequently Asked Questions

What is Propanc Biopharma's stock symbol?

Propanc Biopharma trades on the OTCMKTS under the ticker symbol "PPCB."

When is Propanc Biopharma's next earnings date?

Propanc Biopharma is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Propanc Biopharma.

Has Propanc Biopharma been receiving favorable news coverage?

Media headlines about PPCB stock have trended very negative on Thursday, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Propanc Biopharma earned a media sentiment score of -3.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Propanc Biopharma.

Who are some of Propanc Biopharma's key competitors?

What other stocks do shareholders of Propanc Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Propanc Biopharma investors own include Cronos Group (CRON), Canopy Growth (CGC), Crispr Therapeutics (CRSP), Insys Therapeutics (INSY), Bed Bath & Beyond (BBBY), Novavax (NVAX), General Electric (GE), Xerox (XRX), Charlotte's Web (CWBHF) and Delcath Systems (DCTH).

Who are Propanc Biopharma's key executives?

Propanc Biopharma's management team includes the folowing people:
  • Mr. James Nathanielsz, Acting Chairman, CEO, CFO, Sec., Treasurer & Director (Age 45)
  • Dr. Julian Norman Kenyon, Chief Scientific Officer & Director (Age 71)
  • Prof. Klaus Kutz, Chief Medical Officer & Member of Scientific Advisory Board

How do I buy shares of Propanc Biopharma?

Shares of PPCB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Propanc Biopharma's stock price today?

One share of PPCB stock can currently be purchased for approximately $0.20.

How big of a company is Propanc Biopharma?

Propanc Biopharma has a market capitalization of $262,131.00. Propanc Biopharma employs 1 workers across the globe.View Additional Information About Propanc Biopharma.

What is Propanc Biopharma's official website?

The official website for Propanc Biopharma is http://www.propanc.com/.

How can I contact Propanc Biopharma?

Propanc Biopharma's mailing address is 302/6 BUTLER STREET VICTORIA, CAMBERWELL C3, 3124. The company can be reached via phone at 610398820780 or via email at [email protected]


MarketBeat Community Rating for Propanc Biopharma (OTCMKTS PPCB)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  79 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  116
MarketBeat's community ratings are surveys of what our community members think about Propanc Biopharma and other stocks. Vote "Outperform" if you believe PPCB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PPCB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel